ANEMOCYTE
Live / Registered — Registered — international registration renewed (as of 16 Sept 2025)
What this means for you
Registered since 10 Apr 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79211373
- Registration number
- 5440621
- Mark type
- Word mark
- Filed
- 06 Feb 2017
- Published for opposition
- 23 Jan 2018
- Registered
- 10 Apr 2018
- Attorney of record
- Brian A. Tollefson
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues ] for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues ] for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription ] medicines, namely, [ pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, ] vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes ] ; biological reagents for medical use; medicinal products based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical [ and veterinary ] purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; [ biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; ] [ products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; ] products for personalized medicine made of [ autologous cells or proteins or ] nucleid acids derived from individual genomic sequences; [ preparations made up of cells for medical or clinical use; ] preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]
- Class 042 — Scientific and technological services: Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes
Owner
- ANEMOCYTE S.R.L., GERENZANO (VA), IT
- ANEMOCYTE S.R.L., IT
- ARETA INTERNATIONAL S.R.L., IT
Prosecution history
- 09 Feb 2026 — INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
- 06 Feb 2026 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 16 Sept 2025 — NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
- 16 Sept 2025 — REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
- 22 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 16 Aug 2025 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 06 Jun 2025 — POST REGISTRATION ACTION MAILED - SEC. 71 & 15
- 15 May 2025 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 15 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 15 May 2025 — TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
- 15 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 15 May 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 16 Dec 2024 — POST REGISTRATION ACTION MAILED - SEC. 71 & 15
- 20 Nov 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 09 Apr 2024 — TEAS SECTION 71 & 15 RECEIVED